Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Mandel R. Sher"'
Autor:
Allison Martin Nguyen, Carmen La Rosa, Alexandra G. Cornell, Mandel R. Sher, Jonathan A. Bernstein, Surinder S. Birring, Carla (DeMuro) Romano, Margaret Mayorga, Mirline Milien, Claire Ervin
Publikováno v:
Therapeutic Advances in Respiratory Disease, Vol 18 (2024)
Background: Chronic cough, a cough lasting >8 weeks, includes refractory chronic cough (RCC) and unexplained chronic cough (UCC). Patient-reported outcome (PRO) measures are needed to better understand chronic cough impacts that matter most to patien
Externí odkaz:
https://doaj.org/article/d4b71c179cce4e80b1b366443357246d
Autor:
Vishal Bali, Jonathan Schelfhout, Mandel R. Sher, Anju Tripathi Peters, Gayatri B. Patel, Margaret Mayorga, Diana Goss, Carla (DeMuro) Romano
Publikováno v:
Therapeutic Advances in Respiratory Disease, Vol 18 (2024)
Background: Chronic cough, defined as a cough lasting 8 or more weeks, affects up to 10% of adults. Refractory chronic cough (RCC) is a cough that is uncontrolled despite comprehensive investigation and treatment of comorbid conditions while unexplai
Externí odkaz:
https://doaj.org/article/56000a32c65346eda33d1d3cb4594dfb
Autor:
Seonkyeong Yang, Juan M. Hincapie-Castillo, Xuehua Ke, Jonathan Schelfhout, Helen Ding, Mandel R. Sher, Lili Zhou, Ching-Yuan Chang, Debbie L. Wilson, Wei-Hsuan Lo-Ciganic
Publikováno v:
Journal of Clinical Medicine; Volume 11; Issue 13; Pages: 3671
Using 2003–2018 National Ambulatory Medical Care Survey data for office-based visits and 2003–2018 National Hospital Ambulatory Medical Care Survey data for emergency department (ED) visits, we conducted cross-sectional analyses to examine cough
Autor:
Mandel R. Sher, David Muccino, Zhi Jin Xu, Lorcan McGarvey, Allison Martin Nguyen, Jaclyn A. Smith, Wen-Chi Wu, Alyn H. Morice, Jonathan Schelfhout, Surinder S. Birring
Publikováno v:
Morice, A H, Birring, S S, Smith, J A, McGarvey, L P, Schelfhout, J, Martin Nguyen, A, Xu, Z J, Wu, W C, Muccino, D R & Sher, M R 2021, ' Characterization of Patients With Refractory or Unexplained Chronic Cough Participating in a Phase 2 Clinical Trial of the P2X3-Receptor Antagonist Gefapixant ', Lung, vol. 199, no. 2, pp. 121-129 . https://doi.org/10.1007/s00408-021-00437-7
Morice, A H, Birring, S S, Smith, J A, McGarvey, L P, Schelfhout, J, Martin Nguyen, A, Xu, Z J, Wu, W-C, Muccino, D R & Sher, M R 2021, ' Characterization of Patients With Refractory or Unexplained Chronic Cough Participating in a Phase 2 Clinical Trial of the P2X3-Receptor Antagonist Gefapixant ', Lung, vol. 199, no. 2, pp. 121-129 . https://doi.org/10.1007/s00408-021-00437-7
Lung
Morice, A H, Birring, S S, Smith, J A, McGarvey, L P, Schelfhout, J, Martin Nguyen, A, Xu, Z J, Wu, W-C, Muccino, D R & Sher, M R 2021, ' Characterization of Patients With Refractory or Unexplained Chronic Cough Participating in a Phase 2 Clinical Trial of the P2X3-Receptor Antagonist Gefapixant ', Lung, vol. 199, no. 2, pp. 121-129 . https://doi.org/10.1007/s00408-021-00437-7
Lung
Purpose This analysis assesses clinical characteristics of patients with refractory chronic cough (RCC) or unexplained chronic cough (UCC) enrolled in a phase 2 study to better understand this patient population. Methods Patients with RCC/UCC lasting
Autor:
Lorcan P McGarvey, Zhi Jin Xu, Vivek Iyer, James Krainson, James H. Hull, Mark H Gotfried, Jaclyn A Smith, David Muccino, Gary C Steven, Douglas McQuaid, David I. Bernstein, Gregory Daniel Brooks, David Elkayam, Wen-Chi Wu, Selwyn Spangenthal, Mandel R Sher, Jaclyn A. Smith, Yu-Ping Li, John J Condemi, Ellen R Sher, John R Holcomb, W. Carr, Gary N Gross, SM Parker, Gary D Berman, Ratko Djukanovic, Thomas B. Casale, Jason H Friesen, Krishna Sundar, Christopher E. Brightling, Michael Denenberg, Neil Ettinger, S S Birring, Faisal Alfonso Fakih, Bruce M Prenner, Lorcan McGarvey, Niran J Amar, Jonathan Corren, Tim Harrison, Shaila U Gogate, William W. Storms, Alyn H. Morice, Iftikhar Hussain, Leon S Greos, Anthony Montanaro, Anthony P. Ford, James S Good, Eric J Schenkel, Surinder S. Birring, Thomas R Murphy, Michael S Kaplan, William R Lumry, Jonathan Matz, Michael M. Kitt, Mandel Sher, Alan B Goldsobel, Ian D. Pavord
Publikováno v:
Protocol 012 Investigators 2020, ' Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial ', The Lancet Respiratory Medicine . https://doi.org/10.1016/S2213-2600(19)30471-0
BACKGROUND: Gefapixant is a P2X3 receptor antagonist that has shown promise for the treatment of refractory and unexplained chronic cough. The aim of this study was to evaluate the efficacy of gefapixant compared with placebo after 12 weeks of treatm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bed8062bd34a8ad548083ad97ee59fbd
https://pure.qub.ac.uk/en/publications/gefapixant-a-p2x3-receptor-antagonist-for-the-treatment-of-refractory-or-unexplained-chronic-cough-a-randomised-doubleblind-controlled-parallelgroup-phase-2b-trial(5aa94b05-a819-433a-a265-b0ce6c143476).html
https://pure.qub.ac.uk/en/publications/gefapixant-a-p2x3-receptor-antagonist-for-the-treatment-of-refractory-or-unexplained-chronic-cough-a-randomised-doubleblind-controlled-parallelgroup-phase-2b-trial(5aa94b05-a819-433a-a265-b0ce6c143476).html
Autor:
Kimberley Holt, Shilpi Sen, Jaclyn A. Smith, Peter Butera, Mandel R. Sher, Steven Smith, Zhi Jin Xu, Anthony P. Ford, Michael M. Kitt, Yu-Ping Li
Publikováno v:
Smith, J, Kitt, M M, Butera, P, Smith, S A, Li, Y, Xu, Z J, Holt, K, Sen, S, Sher, M R & Ford, A P 2020, ' Gefapixant in two randomised dose-escalation studies in chronic cough ', European Respiratory Journal . https://doi.org/10.1183/13993003.01615-2019
Background and objectivesGefapixant has previously demonstrated efficacy in the treatment of refractory chronic cough at a high daily dose. The current investigations explore efficacy and tolerability of gefapixant, a P2X3 receptor antagonist, for th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d5c70434c423ae7df0d456c27885bd9
https://doi.org/10.1183/13993003.01615-2019
https://doi.org/10.1183/13993003.01615-2019
Autor:
Lorcan McGarvey, David Muccino, Alyn H. Morice, Surinder S. Birring, Jacky Smith, Mandel R. Sher, Andrew M. Tershakovec, Michael M. Kitt, Zhi Jin Xu, George Philip
Publikováno v:
World Allergy Organization Journal, Vol 13, Iss 8, Pp 100209-(2020)
Autor:
Alyn H. Morice, Zhi Jin Xu, Surinder S. Birring, Wen-Chi Wu, Jaclyn A. Smith, Michael M. Kitt, Lorcan McGarvey, Mandel R. Sher, David Muccino, Andrew M. Tershakovec
Publikováno v:
Clinical Problems.
Objectives: We evaluated demographic and baseline characteristics associated with efficacy response with MK-7264, a P2X3 antagonist, in refractory chronic cough patients. Methods: Patients with chronic cough (duration of ≥1 year) refractory to trea
Autor:
Michael M. Kitt, Surinder Birring, Alyn H. Morice, Jaclyn A. Smith, Lorcan McGarvey, Mandel R. Sher, Anthony P. Ford
Publikováno v:
Clinical Problems Others.
Introduction: MK-7264 (formerly AF-219) is a P2X3 receptor antagonist that has been shown to reduce cough frequency in patients with chronic cough. Methods: This 12-week, double-blind, parallel group study conducted at 46 sites in the US and UK rando
Publikováno v:
5.1 Airway Pharmacology and Treatment.
Introduction: Chronic cough is a challenging problem as available medications lack proven efficacy. AF-219, a P2X3 antagonist, effectively reduced cough frequency in 2 previous phase 2 trials at doses 50-600mg BID1. The present study explored the dos